Title | PEHO Syndrome May Represent Phenotypic Expansion at the Severe End of the Early-Onset Encephalopathies. |
Publication Type | Journal Article |
Year of Publication | 2016 |
Authors | Gawlinski, P, Posmyk, R, Gambin, T, Sielicka, D, Chorazy, M, Nowakowska, B, Jhangiani, SN, Muzny, DM, Bekiesinska-Figatowska, M, Bal, J, Boerwinkle, E, Gibbs, RA, Lupski, JR, Wiszniewski, W |
Journal | Pediatr Neurol |
Volume | 60 |
Pagination | 83-7 |
Date Published | 2016 Jul |
ISSN | 1873-5150 |
Abstract | BACKGROUND: Progressive encephalopathy with edema, hypsarrhythmia and optic atrophy (PEHO) syndrome is a distinct neurodevelopmental disorder. Patients without optic nerve atrophy and brain imaging abnormalities but fulfilling other PEHO criteria are often described as a PEHO-like syndrome. The molecular bases of both clinically defined conditions remain unknown in spite of the widespread application of genome analyses in both clinic and research. METHODS: We enrolled two patients with a prior diagnosis of PEHO and two individuals with PEHO-like syndrome. All four individuals subsequently underwent whole-exome sequencing and comprehensive genomic analysis. RESULTS: We identified disease-causing mutations in known genes associated with neurodevelopmental disorders including GNAO1 and CDKL5 in two of four individuals. One patient with PEHO syndrome and a de novoGNAO1 mutation was found to have an additional de novo mutation in HESX1 that is associated with optic atrophy. CONCLUSIONS: We hypothesize that PEHO and PEHO-like syndrome may represent a severe end of the spectrum of the early-onset encephalopathies and, in some instances, its complex phenotype may result from an aggregated effect of mutations at two loci. |
DOI | 10.1016/j.pediatrneurol.2016.03.011 |
Alternate Journal | Pediatr. Neurol. |
PubMed ID | 27343026 |
PubMed Central ID | PMC5125779 |
Grant List | K23 NS078056 / NS / NINDS NIH HHS / United States R01 NS058529 / NS / NINDS NIH HHS / United States U54 HG006542 / HG / NHGRI NIH HHS / United States UM1 HG006542 / HG / NHGRI NIH HHS / United States |